<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The introduction of dipeptidyl-peptidase IV inhibitors (DPP-4 inhibitors) brought a novel class of insulinotropic agents into the treatment options for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This paper compares the actions, clinical efficacy and safety of sulphonylureas with those of the DPP-4 inhibitors </plain></SENT>
<SENT sid="2" pm="."><plain>First, the mode of action of both classes of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents is described </plain></SENT>
<SENT sid="3" pm="."><plain>Then clinical studies for both substances in monotherapy and combination therapies are compared concerning their effects on glycaemic parameters and long-term duration of action </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> incidence and other adverse effects are compared and data on cardiovascular parameters and endpoints are summarized </plain></SENT>
<SENT sid="5" pm="."><plain>The effects of sulphonylureas and DPP-4 inhibitors on beta-cell function and beta-cell mass are highlighted </plain></SENT>
<SENT sid="6" pm="."><plain>The present and future indications for both sulphonylureas and DPP-4 inhibitors are discussed </plain></SENT>
</text></document>